Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 9/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.45 |
| ▸ | HTR2C | P28335 | 7/20 | 0.44 |
| ▸ | HTR2B | P41595 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | REN | P00797 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29613171 | 1.00 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DHTR2C | |
| SCHEMBL19270702 | 0.88 | HTR2C (0.39) | PDE4APDE4BPDE4CPDE4DHTR2C | |
| SCHEMBL18424206 | 0.82 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DHTR2C | |
| SCHEMBL18424220 | 0.82 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DHTR2C | |
| SCHEMBL18423314 | 0.82 | REN (0.48) | PDE4APDE4BPDE4CPDE4DREN | |
| SCHEMBL18423253 | 0.82 | HTR2C (0.41) | HTR2CHTR2BHTR2A | |
| SCHEMBL11844345 | 0.81 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19252806 | 0.81 | HTR2C (0.42) | PDE4APDE4BPDE4CPDE4DHTR2C | |
| SCHEMBL18425177 | 0.81 | HTR2C (0.44) | PDE4APDE4BPDE4CPDE4DHTR2C | |
| SCHEMBL4129415 | 0.80 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071447-B | Tetracyclic pyridinone compounds as antiviral agents | 诺华股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| EP-3416946-B1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2021-09-15 | — | — | EP | disclosed |
| EP-3416946-B1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2021-09-15 | — | — | EP | disclosed |
| US-20200270265-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| US-20200270265-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| EP-3416946-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | Novartis AG (CH) | 2018-12-26 | — | — | EP | disclosed |
| US-10093673-B2 | Tetracyclic pyridone compounds as antivirals | NOVARTIS AG (CH) | 2018-10-09 | — | — | US | disclosed |
| US-20180030053-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-20180030053-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-9845325-B2 | Tetracyclic pyridone compounds as antivirals | NOVARTIS AG (CH) | 2017-12-19 | — | — | US | disclosed |
| US-9845325-B2 | Tetracyclic pyridone compounds as antivirals | NOVARTIS AG (CH) | 2017-12-19 | — | — | US | disclosed |
| WO-2017140821-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017140821-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS AG (CH) | 2017-08-24 | — | — | WO | disclosed |
| US-20170240548-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2017-08-24 | — | — | US | disclosed |
| US-20170240548-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270265-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | PNPO, HAVCR2, TYMP | PDE4A 2146/4885PDE4B 1845/4885PDE4C 1973/4885 |
| US-10093673-B2 | Tetracyclic pyridone compounds as antivirals | PNPO, HAVCR2, TYMP | PDE4A 2146/4885PDE4B 1845/4885PDE4C 1973/4885 |
| US-20180030053-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | PNPO, HAVCR2, TYMP | PDE4A 2146/4885PDE4B 1845/4885PDE4C 1973/4885 |
| US-20170240548-A1 | TETRACYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS | PNPO, HAVCR2, TYMP | PDE4A 2146/4885PDE4B 1845/4885PDE4C 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.